GH Research plc Unveils Pipeline Progress on Mebufotenin Programs for Depression

Reuters11-06

GH Research plc Unveils Pipeline Progress on Mebufotenin Programs for Depression

GH Research plc $(GHRS)$ has provided an update on its clinical development pipeline, highlighting progress in treatments for psychiatric disorders. The company's lead product candidate, GH001, an inhaled formulation of mebufotenin, is advancing towards a Phase 3 trial for treatment-resistant depression (TRD) with initiation planned in 2026. Recent Phase 2b trial data demonstrated a 57.5% remission rate and a 60% response rate at Day 8 for patients receiving GH001, compared to 0% for placebo, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Additional pipeline candidates include GH002 for intravenous administration, which has completed a Phase 1 trial in healthy volunteers. As of September 30, 2025, GH Research reported $293.9 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581062067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581062067","market":"fut","top_or_hot":-1,"title":"GH Research plc Unveils Pipeline Progress on Mebufotenin Programs for Depression","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GH Research plc Unveils Pipeline Progress on Mebufotenin Programs for Depression\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GH Research plc <a href=\"https://laohu8.com/S/GHRS\">$(GHRS)$</a> has provided an update on its clinical development pipeline, highlighting progress in treatments for psychiatric disorders. The company's lead product candidate, GH001, an inhaled formulation of mebufotenin, is advancing towards a Phase 3 trial for treatment-resistant depression (TRD) with initiation planned in 2026. Recent Phase 2b trial data demonstrated a 57.5% remission rate and a 60% response rate at Day 8 for patients receiving GH001, compared to 0% for placebo, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Additional pipeline candidates include GH002 for intravenous administration, which has completed a Phase 1 trial in healthy volunteers. As of September 30, 2025, GH Research reported $293.9 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GH Research plc Unveils Pipeline Progress on Mebufotenin Programs for Depression</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGH Research plc Unveils Pipeline Progress on Mebufotenin Programs for Depression\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GH Research plc Unveils Pipeline Progress on Mebufotenin Programs for Depression\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        GH Research plc <a href=\"https://laohu8.com/S/GHRS\">$(GHRS)$</a> has provided an update on its clinical development pipeline, highlighting progress in treatments for psychiatric disorders. The company's lead product candidate, GH001, an inhaled formulation of mebufotenin, is advancing towards a Phase 3 trial for treatment-resistant depression (TRD) with initiation planned in 2026. Recent Phase 2b trial data demonstrated a 57.5% remission rate and a 60% response rate at Day 8 for patients receiving GH001, compared to 0% for placebo, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Additional pipeline candidates include GH002 for intravenous administration, which has completed a Phase 1 trial in healthy volunteers. As of September 30, 2025, GH Research reported $293.9 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL3b3dMZ:1","article_id":"2581062067","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581062067","pubTimestamp":1762430971,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GH Research plc  has provided an update on its clinical development pipeline, highlighting progress in treatments for psychiatric disorders. The company's lead product candidate, GH001, an inhaled formulation of mebufotenin, is advancing towards a Phase 3 trial for treatment-resistant depression  with initiation planned in 2026. Recent Phase 2b trial data demonstrated a 57.5% remission rate and a 60% response rate at Day 8 for patients receiving GH001, compared to 0% for placebo, as measured by the Montgomery-sberg Depression Rating Scale . Additional pipeline candidates include GH002 for intravenous administration, which has completed a Phase 1 trial in healthy volunteers. As of September 30, 2025, GH Research reported $293.9 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4539":"次新股","GHRS":"GH Research PLC"},"translate_title":"GH Research plc公布美布福替宁治疗抑郁症项目的管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GHRS":0.9},"content_text":"GH Research plc Unveils Pipeline Progress on Mebufotenin Programs for Depression\n    \n\n        GH Research plc $(GHRS)$ has provided an update on its clinical development pipeline, highlighting progress in treatments for psychiatric disorders. The company's lead product candidate, GH001, an inhaled formulation of mebufotenin, is advancing towards a Phase 3 trial for treatment-resistant depression (TRD) with initiation planned in 2026. Recent Phase 2b trial data demonstrated a 57.5% remission rate and a 60% response rate at Day 8 for patients receiving GH001, compared to 0% for placebo, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). Additional pipeline candidates include GH002 for intravenous administration, which has completed a Phase 1 trial in healthy volunteers. As of September 30, 2025, GH Research reported $293.9 million in cash, cash equivalents, and marketable securities. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581062067","isCrawlerRequest":true}